The PATHOMIQ AI Platform is Powered by Our Phenotype Atlas
The first of its kind, our comprehensive phenotype atlas combines expert pathologist supervision with cutting edge AI-learned information. Trained using thousands of slides spanning multiple tissues from a diverse set of medical institutions, this powerful asset allows us to quickly deploy our platform to new and specific use-cases using only a minimal amount of outcome data.
Outcome Prediction
The PATHOMIQ AI Platform outperforms clinical and genomic gold standards. We have shown to accurately predict risk of metastasis and response to anti-androgen therapy in prostate, as well as pathologic complete response in triple negative breast cancer.
Efficient Screening Capability
Our platform can predict genotypes and molecular alterations directly from H&E-stained WSIs with high accuracy, enabling timely and optimal treatment decision-making for positive clinical outcomes.
The PATHOMIQ AI Platform Predicts Alterations in Prostate and Breast
Biomarker Discovery
Our platform identifies regions of interest that are predictive to specific therapy response, allowing for focused molecular analysis.
Phenotype-guided ROIs Capture Molecular Changes
Precision Cancer Grading
Our powerful method allows for precision gland-level cancer grading to improve accuracy of pathologists.
